Search

A comprehensive immunogenicity scheme is proposed to examine immune response of bovine sourced hemostasis collagen sponge to establish foundation for further researches and decrease the incidence of adverse reaction in clinical trials. Compared with negative control group without any implant, spleen and lymph nodes morphology show no apparent swelling in mice with different doses of collagen sponge implants. Immune cells population, especially lymph nodes cells population, is practically coincident with organs. However, splenic cells display slight proliferation in early phase following collagen sponge implantation. Splenic cells apoptosis also demonstrates no significant difference among all groups. T lymphocytes subsets, CD4/CD8 cells ratio, in spleen and lymph nodes are practically normal. Splenic cells Ki67 + proportions do not exhibit significant difference between collagen sponge groups and negative control group. Humoral response is determined by detection of IgG and IgM concentration in serum, not exhibiting remarkable increase with collagen sponge implantation, compared to the drastic increase in positive control group with bovine tendon implantation. Local analysis around implants by hematoxylin-eosin staining discovers slight cell infiltration around collagen sponge. Tumour necrosis factor-α immunostaining indicates slight inflammation in early phase following collagen sponge implantation, but interferon-γ immunostaining is negligible even in positive control group. Collagen sponge, especially in high dose, may have evoked benign immune response in BALB/c mice, but this response is transient. The present evaluation scheme for immune response is integrated and comprehensive, suitable for various biomaterials. [ABSTRACT FROM AUTHOR]

Osteoarthritis is a degenerative joint disease, typified by the loss in the quality of cartilage and bone at the interface of a synovial joint, resulting in pain, stiffness and reduced mobility. The current surgical treatment for advanced stages of the disease is joint replacement, where the non-surgical therapeutic options or less invasive surgical treatments are no longer effective. These are major surgical procedures which have a substantial impact on patients' quality of life and lifetime risk of requiring revision surgery. Treatments using regenerative methods such as tissue engineering methods have been established and are promising for the early treatment of cartilage degeneration in osteoarthritis joints. In this approach, 3-dimensional scaffolds (with or without cells) are employed to provide support for tissue growth. However, none of the currently available tissue engineering and regenerative medicine products promotes satisfactory durable regeneration of large cartilage defects. Herein, we discuss the current regenerative treatment options for cartilage and osteochondral (cartilage and underlying subchondral bone) defects in the articulating joints. We further identify the main hurdles in osteochondral scaffold development for achieving satisfactory and durable regeneration of osteochondral tissues. The evolution of the osteochondral scaffolds - from monophasic to multiphasic constructs - is overviewed and the osteochondral scaffolds that have progressed to clinical trials are examined with respect to their clinical performances and their potential impact on the clinical practices. Development of an osteochondral scaffold which bridges the gap between small defect treatment and joint replacement is still a grand challenge. Such scaffold could be used for early treatment of cartilage and osteochondral defects at early stage of osteoarthritis and could either negate or delay the need for joint replacements.

It has been well recognized that the development and use of artificial materials with high osteogenic ability is one of the most promising means to replace bone grafting that has exhibited various negative effects. The biomimetic features and unique physiochemical properties of nanomaterials play important roles in stimulating cellular functions and guiding tissue regeneration. But efficacy degree of some nanomaterials to promote specific tissue formation is still not clear. We hereby comparatively studied the osteogenic ability of our treated multi-walled carbon nanotubes (MCNTs) and the main inorganic mineral component of natural bone, nano-hydroxyapatite (nHA) in the same system, and tried to tell the related mechanism. In vitro culture of human adipose-derived mesenchymal stem cells (HASCs) on the MCNTs and nHA demonstrated that although there was no significant difference in the cell adhesion amount between on the MCNTs and nHA, the cell attachment strength and proliferation on the MCNTs were better. Most importantly, the MCNTs could induce osteogenic differentiation of the HASCs better than the nHA, the possible mechanism of which was found to be that the MCNTs could activate Notch involved signaling pathways by concentrating more proteins, including specific bone-inducing ones. Moreover, the MCNTs could induce ectopic bone formation in vivo while the nHA could not, which might be because MCNTs could stimulate inducible cells in tissues to form inductive bone better than nHA by concentrating more proteins including specific bone-inducing ones secreted from M2 macrophages. Therefore, MCNTs might be more effective materials for accelerating bone formation even than nHA., Competing Interests: There are no conflicts of interest to declare., (© 2020 [The Author/The Authors].)